- Home
- CRDF vs AIRS Comparison
CRDF vs AIRS Comparison
Compare CRDF & AIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- AIRS
- Stock Information
- Founded
- CRDF 1999
- AIRS 2012
- Country
- CRDF United States
- AIRS United States
- Employees
- CRDF N/A
- AIRS N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- AIRS Medical/Nursing Services
- Sector
- CRDF Health Care
- AIRS Health Care
- Exchange
- CRDF Nasdaq
- AIRS Nasdaq
- Market Cap
- CRDF 240.2M
- AIRS 277.3M
- IPO Year
- CRDF N/A
- AIRS 2021
- Fundamental
- Price
- CRDF $3.45
- AIRS $5.33
- Analyst Decision
- CRDF Strong Buy
- AIRS Hold
- Analyst Count
- CRDF 3
- AIRS 3
- Target Price
- CRDF $10.33
- AIRS $5.00
- AVG Volume (30 Days)
- CRDF 1.4M
- AIRS 286.7K
- Earning Date
- CRDF 02-27-2025
- AIRS 02-25-2025
- Dividend Yield
- CRDF N/A
- AIRS N/A
- EPS Growth
- CRDF N/A
- AIRS N/A
- EPS
- CRDF N/A
- AIRS N/A
- Revenue
- CRDF $688,000.00
- AIRS $188,780,000.00
- Revenue This Year
- CRDF $25.03
- AIRS N/A
- Revenue Next Year
- CRDF N/A
- AIRS $9.93
- P/E Ratio
- CRDF N/A
- AIRS N/A
- Revenue Growth
- CRDF 49.57
- AIRS N/A
- 52 Week Low
- CRDF $1.44
- AIRS $2.92
- 52 Week High
- CRDF $6.42
- AIRS $9.20
- Technical
- Relative Strength Index (RSI)
- CRDF 45.05
- AIRS 44.99
- Support Level
- CRDF $3.33
- AIRS $3.83
- Resistance Level
- CRDF $4.89
- AIRS $5.15
- Average True Range (ATR)
- CRDF 0.31
- AIRS 0.49
- MACD
- CRDF -0.15
- AIRS -0.03
- Stochastic Oscillator
- CRDF 10.56
- AIRS 61.48
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.